

pDUO2-mCD14/TLR4

A plasmid coexpressing the mouse CD14 and TLR4 genes

Catalog code: pduo2-mcd14tlr4

<https://www.invivogen.com/pduo-cd14-tlr4>

For research use only

Version 19I24-MM

PRODUCT INFORMATION

Contents

- 20 µg of pDUO2-mCD14/TLR4 provided as lyophilized DNA
- 1 ml of Hygromycin B Gold at 100 mg/ml

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store Hygromycin B Gold at 4°C or -20°C. The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

Toll-Like receptors (TLRs) play a critical role in early innate immunity to invading pathogens by sensing microorganisms. These evolutionary conserved receptors, homologues of the *Drosophila* Toll gene, recognize highly conserved structural motifs only expressed by microbial pathogens, called pathogen-associated microbial patterns (PAMPs). PAMPs include various bacterial cell wall components such as lipopolysaccharides (LPS), peptidoglycans and lipopeptides, as well as flagellin, bacterial DNA and viral double-stranded RNA. Stimulation of TLRs by PAMPs initiates a signaling cascade that involves a number of proteins, such as MyD88 and IRAK. This signaling cascade leads to the activation of the transcription factor NF-κB which induces the secretion of pro-inflammatory cytokines and effector cytokines that direct the adaptive immune response.

To date, ten toll-like receptors have been reported in humans (TLR1 to TLR10) and only nine in mice (TLR1 to TLR9). In many instances, TLRs require the presence of a co-receptor to initiate the signaling cascade. One example is TLR4 which interacts with MD2 and CD14 to induce NF-κB in response to LPS stimulation.

pDUO2 is an expression vector designed to co-express two TLRs or TLR-related genes known to interact with each other.

The genes cloned into pDUO2 comprise the coding sequence (without introns) from the ATG to the Stop codon.

PLASMID FEATURES

- **Murine CD14 (1101 bp)/Murine TLR2 (2505 bp)**
TLR4 is the receptor for Gram-negative lipopolysaccharide (LPS). The TLR4 gene was shown to be mutated in C3H/HeJ and C57BL/10ScCr mice, both of which are low responders to LPS¹. However, TLR4 alone is not sufficient to confer LPS responsiveness. TLR4 requires MD-2, a secreted molecule, to functionally interact with LPS². TLR4 physically associates with MD2, and together with a third protein called CD14, this complex is responsible for LPS recognition and signaling³.
- **hFerH and hFerL composite promoters:** Ferritin is a 24 subunit protein composed of two subunit types, termed H (heavy) and L (light), which perform complementary functions in the protein. Ferritin is ubiquitously expressed. Its synthesis is highly regulated by the iron status of the cell. The iron regulation is achieved at the translational level through the interaction between the iron-responsive element (IRE), located in the 5' untranslated region (5'UTR) of the ferritin mRNAs, and the iron regulatory protein³. To eliminate the iron regulation of the ferritin promoters, the 5'UTR of FerH and FerL have been replaced by the 5'UTR of the mouse and chimpanzee elongation factor 1 (EF1) genes, respectively.
- **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range. The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells. Furthermore, the SV40 enhancer is able to direct nuclear localization of plasmids⁴.
- **CMV enhancer:** The major immediate early enhancer of the human cytomegalovirus (HCMV), located between nucleotides -118 and -524, is composed of unique and repeated sequence motifs. The HCMV enhancer can substitute for the 72-bp repeats of SV40 and is severalfold more active than the SV40 enhancer⁵.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA. The efficiency of this signal was first described by Carswell *et al.*⁶
- **pMB1 ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression⁷.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **Hph (hygromycin resistance gene):** confers resistance to Hygromycin B both in *E. coli* and mammalian cells. In bacteria, *hph* is expressed from the constitutive *E. coli* EM7 promoter. In mammalian cells, *hph* is transcribed from the human FerH composite promoter as a polycistronic mRNA and translated via the FMDV IRES
- **EF1 pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Hygromycin B usage:


This antibiotic can be used for *E. coli* at 50-100 µg/ml in liquid or solid media and at 50-500 µg/ml to select Hygromycin-resistant mammalian cells.

References

1. Poltorak A. *et al.*, 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* 282(5396):2085-8.
2. Ozinsky A. *et al.*, (2000). The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. *PNAS* 97(25):13766-71.
3. Eisenstein R.S. & Munro H.N., 1990. Translational regulation of ferritin synthesis by iron. *Enzyme* 44(1-4):42-58.
4. Dean D.A. *et al.* 1999. Sequence requirements for plasmid nuclear import. *Exp. Cell. Res.* 253:713-22.
5. Boshart M. *et al.* 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 141(2):521-30.
6. Carswell S. & Alwine J.C., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258.
7. Ramesh N. *et al.* 1996. High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. *Nucleic Acids Res.* 24(14):2697-700.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
 InvivoGen USA (International): +1 (858) 457-5873
 InvivoGen Europe: +33 (0) 5-62-71-69-39
 InvivoGen Hong Kong: +852 3622-3480
 E-mail: info@invivogen.com



AvrII (7705)

7701 TGCTCCTAGGAGATCGCCTCTTTGTTTAAGGAACATTTGCATCCTCTGCTAGGAGCAGGTTTCCCAATGACACAAAACGTGCAACTTGAACCTCCGCC
358▶ euLeuLeuGlyAspArgLeuPheVal ●●●
7801 TGGTCTTCCAGGTCTAGAGGGTAACACTTTGACTGCGTTTGCTCCACGCTCGATCCACTGGCGAGTGTTAGTAACAGCACTGTTGCTTCGTAGCGG
7901 AGCATGACGGCCGTGGAACTCCTCCTTGTAACAAGGACCACGGGGCCAAAAGCCACGCCACACGGGCCCATGTGTGCAACCCAGCACGGCGA
8001 CTTTACTGCGAAACCACTTTAAAGTGACATTGAAACTGGTACCACACACTGGTGACAGGCTAAGGATGCCCTTCAGGTACCCCGAGGTAACACGGCA

BstEII (8172)

8101 ACTCGGGATCTGAGAAGGGGACTGGGGCTTCTATAAAAGCGCTCGGTTTAAAAAGCTTCTATGCCTGAATAGGTGACCCGGAGGTGGCACCTTTCCTTTG

AseI (8240)

8201 CAATTACTGACCTATGAATACAACCTGACTGTTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACTCACTATAGGAGGGCCACCAT
8301 GAAGAAACCTGAACTGACAGCAACTTCTGTTGAGAAGTTTCTCATTGAAAAATTTGATTCTGTTTCTGATCTCATGCAGCTGCTGAAGGTGAAGAAAAGC
1▶ tLysLysProGluLeuThrAlaThrSerValGluLysPheLeuIleGluLysPheAspSerValSerAspLeuMetGluLeuSerGluGlyGluGluSer
8401 AGAGCCTTTTCTTTGATGTTGGAGGAAGAGGTTATGTTCTGAGGGTCAATTTCTGTGCTGATGTTTTTACAAAGACAGATATGTTTACAGACACTTTG
35▶ ArgAlaPheSerPheAspValGlyGlyArgGlyTyrValLeuArgValAsnSerCysAlaAspGlyPheTyrLysAspArgTyrValTyrArgHisPheA
8501 CCTCTGCTGCTGCCAATCCAGAAGTCTGGCATTGGAGAATTTCTGAATCTCTCACCTACTGCATCAGCAGAAGAGCACAAAGGAGTCACTCTCCA
68▶ lAserAlaAlaLeuProIleProGluValLeuAspIleGlyGluPheSerGluSerLeuThrTyrCysIleSerArgArgAlaGluGlyValThrLeuGlu
8601 GGATCTCCCGAAACTGAGCTGCCAGCTGTTCTGCAACCTGTGCTGAAGCAATGGATGCCATTGCAGCAGCTGATCTGAGCCAAACCTCTGGATTGGT
101▶ nAspLeuProGluThrGluLeuProAlaValLeuGluNProValAlaGluAlaMetAspAlaIleAlaAlaAlaAspLeuSerGluThrSerGlyPheGly
8701 CCTTTGGTCCCAAGGCATTGGTCAGTACACCACTGGAGGGATTTCATTTGTGCCATTGCTGATCCTCATGTCTATCACTGGCAGACTGTGATGGATG
135▶ ProPheGlyProGluGlyIleGlyGluNThrThrTrpArgAspPheIleCysAlaIleAlaAspProHisValTyrHisTrpGluNThrValMetAspA
8801 ACACAGTTTCTGCTTCTGTTGCTCAGGCACTGGATGAACCTCATGCTGTGGGCAGAAGATTGCTCTGAAGTCAGACACCTGGTCCATGCTGATTTTGGAAAG
168▶ spThrValSerAlaSerValAlaGluNAlaLeuAspGluLeuMetLeuTrpAlaGluAspCysProGluValArgHisLeuValHisAlaAspPheGlySe
8901 CAACAATGTTCTGACAGACAATGGCAGAATCACTGCAGTCATTGACTGGTCTGAAGCCATGTTTGGAGATTCTCAATATGAGGTTGCCAACATTTTTTT
201▶ rAsnAsnValLeuThrAspAsnGlyArgIleThrAlaValIleAspTrpSerGluAlaMetPheGlyAspSerGluNThrGluValAlaAsnIlePhePhe
9001 TGGAGACCTTGGCTGGCTGGCATGGAACAACAACAAGATATTTGAAAGAAAGACCCAGAAGCTGGCTGGTTCCCCAGACTGAGAGCCTACATGCTCA
235▶ TrpArgProTrpLeuAlaCysMetGluGluGluNThrArgTyrPheGluArgArgHisProGluLeuAlaGlySerProArgLeuArgAlaTyrMetLeuA
9101 GAATTGGCCTGGACCAACTGTATCAATCTCTGGTTGATGGAACCTTTGATGATGCTGCTGGGCACAAGGAAGATGTGATGCCATTGTGAGGTCTGGTGC
268▶ rglIleGlyLeuAspGluNLeuTyrGluNThrLeuValAspGlyAsnPheAspAspAlaAlaTrpAlaGluGlyArgCysAspAlaIleValArgSerGlyAl
9201 TGGAACTGTTGGAAGAAGCTCAAATGCAAGAAGTCTGCTGCTGTTGGACTGATGGATGTTGAAAGTTCTGGCTGACTCTGGAACAGGAGACCTCTCC
301▶ aGlyThrValGlyArgThrGluIleAlaArgArgSerAlaAlaValTrpThrAspGlyCysValGluValLeuAlaAspSerGlyAsnArgArgProSer
9301 ACAAGACCCAGAGCCAAGGAATGAATATTAGCTAGATTATCCCTAATACCTGCCACCCACTCTTAATCAGTGGTGAAGAAGCGTCTCAGAACTGTTG
335▶ ThrArgProArgAlaLysGlu ●●●
9401 TTTCAATTGGCCATTTAAGTTTAGTAGTAAAAGACTGGTTAATGATAACAATGCATCGTAAAACCTTTCAGAAGGAAAGGAGAATGTTTGTGGACCACT

ScaI (9553)

9501 TGGTTTTCTTTTTGCGTGTGGCAGTTTTAAGTTATTAGTTTTTAAAATCAGTACTTTTTAATGGAAACAACCTTGACCAAAAATTTGTCACAGAATTTTG
9601 AGACCCATTAAGTAAATGAGAAACCTGTGTTCCTTTGGTCAACACCAGACATTTAGGTGAAAGACATCTAATTTCTGGTTTTACGAATCTGGA
9701 AACTTCTTGAAGTGAATTTCTGAGTTAACACTTCTGGTGGAGAATAGGGTGTGTTTTCCCCACATAATTGAAAGGGGAAGGAATATCATTAAAGC
9801 TATGGGAGGGTTGCTTTGATTACAACACTGGAGAGAAATGAGCATGTTGCTGATTGCCTGTCACTAAAACAGGCCAAAACCTGAGTCTTGGGTTGCAT
9901 AGAAAGCTG